19.09.2022 14:16:23
|
Seagen: FDA To Review SNDA For Tucatinib In Combination With Trastuzumab
(RTTNews) - Seagen Inc. (SGEN) said FDA has accepted for Priority Review the supplemental New Drug Application seeking accelerated approval for TUKYSA in combination with trastuzumab for adult patients with HER2-positive colorectal cancer who have received at least one prior treatment regimen for unresectable or metastatic disease. The sNDA submission is based on the results of the phase 2 MOUNTAINEER trial. The FDA has set a target action date of January 19, 2023.
In February 2022, Seagen initiated the global phase 3 MOUNTAINEER-03 clinical trial. It is intended to serve as a confirmatory trial in the U.S. and to support global filings.
For More Such Health News, visit rttnews.com.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Seattle Genetics Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |